BLOOMFIELD, Conn. & PHILADELPHIA--(BUSINESS WIRE)--CIGNA (NYSE:CI) and EMD Serono, Inc. have entered into the nation’s first outcomes-based contract for a specialty medication, aimed at improving the health of people with multiple sclerosis (MS).
BLOOMFIELD, Conn. & PHILADELPHIA--(BUSINESS WIRE)--CIGNA (NYSE:CI) and EMD Serono, Inc. have entered into the nation’s first outcomes-based contract for a specialty medication, aimed at improving the health of people with multiple sclerosis (MS).
